Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms
- PMID: 39172037
- PMCID: PMC11340643
- DOI: 10.1099/jgv.0.002010
Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms
Abstract
Rhabdoviral vectors can induce lysis of cancer cells. While studied almost exclusively at 37 °C, viruses are subject to a range of temperatures in vivo, including temperatures ≤31 °C. Despite potential implications, the effect of temperatures <37 °C on the performance of rhabdoviral vectors is unknown. We investigated the effect of low anatomical temperatures on two rhabdoviruses, vesicular stomatitis virus (VSV) and Maraba virus (MG1). Using a metabolic resazurin assay, VSV- and MG1-mediated oncolysis was characterized in a panel of cell lines at 28, 31, 34 and 37 °C. The oncolytic ability of both viruses was hindered at 31 and 28 °C. Cold adaptation of both viruses was attempted as a mitigation strategy. Viruses were serially passaged at decreasing temperatures in an attempt to induce mutations. Unfortunately, the cold-adaptation strategies failed to potentiate the oncolytic activity of the viruses at temperatures <37 °C. Interestingly, we discovered that viral replication was unaffected at low temperatures despite the abrogation of oncolytic activity. In contrast, the proliferation of cancer cells was reduced at low temperatures. Equivalent oncolytic effects could be achieved if cells at low temperatures were treated with viruses for longer times. This suggests that rhabdovirus-mediated oncolysis could be compromised at low temperatures in vivo where therapeutic windows are limited.
Keywords: oncolytic; rhabdovirus; temperature; viral vector.
Conflict of interest statement
B.W.B. and B.A.M. are the Chief Operating Officer and Chief Executive Officer, respectively, of ImmunoCeutica Inc. (ICI), which is dedicated to the research and development of immunoceuticals. B.A.M. serves as a scientific advisor for Canadian COVID Care Alliance (CCCA). Neither ICI nor CCCA were involved in any way with this manuscript and the research it describes. B.W.B. and B.A.M. have received honoraria for speaking engagements and have given paid expert testimony in service to courts for their expertise in viral immunology and immunogenetics, respectively. The other authors have no potential conflicts of interest to declare. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Similar articles
-
METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state.J Virol. 2025 May 20;99(5):e0228424. doi: 10.1128/jvi.02284-24. Epub 2025 Apr 11. J Virol. 2025. PMID: 40214229 Free PMC article.
-
Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.Viruses. 2024 Dec 25;17(1):16. doi: 10.3390/v17010016. Viruses. 2024. PMID: 39861805 Free PMC article. Review.
-
Thermal stability and storage of human insulin.Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD015385. doi: 10.1002/14651858.CD015385.pub2. Cochrane Database Syst Rev. 2023. PMID: 37930742 Free PMC article.
-
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2. Cochrane Database Syst Rev. 2016. PMID: 27098439 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources